Peptide therapy represents one of the most significant growth areas in cash-pay medicine, but the legal environment is complex and evolving. This guide provides medical practices with a complete reference for the regulatory, legal, and compliance considerations of offering peptide therapy in 2026.
Important: This article is for informational purposes only and does not constitute legal advice. The regulatory environment for peptides is changing rapidly. Consult qualified healthcare legal counsel before making prescribing or business decisions based on this information.
FDA Bulk Drug Substance Categories
The FDA maintains a system for categorizing bulk drug substances that determines whether they can be legally compounded. Understanding this system is foundational to peptide therapy compliance.
How the Category System Works
A 503A pharmacy may compound from a bulk drug substance (the raw ingredient) only if the substance has a USP monograph, is a component of an FDA-approved drug, or is on the FDA’s 503A bulks list. While FDA works through substances nominated for that list, it sorts them into three interim categories under Section 503A of the Federal Food, Drug, and Cosmetic Act. 503B outsourcing facilities follow a separate list.
Category 1: Under Evaluation
Category 1 substances were nominated with sufficient supporting information and are still under evaluation. While that evaluation continues, FDA does not intend to take action against a 503A pharmacy that compounds with them, provided the other conditions of its interim policy are met. In practice:
- 503A pharmacies can compound them pursuant to a valid patient-specific prescription from a licensed prescriber
- Prescribers can write prescriptions for those compounded formulations
- The permission is interim: it lasts until FDA decides whether to add the substance to the 503A bulks list
Peptides in Category 1 as of May 2026 include GHK-Cu (non-injectable routes only), glutathione, NAD+, and Vasoactive Intestinal Peptide.
Category 2: Significant Safety Risks
Category 2 substances were nominated with sufficient information, but FDA has identified significant safety risks, so the interim permission does not apply. As of May 14, 2026, the only peptide in Category 2 is Kisspeptin-10. The FDA’s bulk drug substance lists are the authoritative source for current classifications.
Category 3: Nominated Without Adequate Support
Category 3 substances were nominated without enough supporting information for FDA to evaluate them, so the interim permission does not apply and they cannot be compounded under it.
A substance in no category at all, because it was never nominated or its nomination was withdrawn, has no interim permission either. That is where BPC-157 and most of the peptides below now sit.
Being in no category is not a problem for every peptide. Section 503A also allows compounding from a substance that has a USP monograph or is a component of an FDA-approved drug, with no bulks-list place needed. That is the basis for gonadorelin (USP monographs), PT-141 (the active ingredient of Vyleesi), and sermorelin (the active ingredient of Geref, discontinued but not withdrawn for safety reasons). The FDA Category 1 peptides guide covers each one.
The February 2026 HHS Announcement
On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced plans to move approximately 14 of the 19 peptides then classified as Category 2 back to Category 1. The announcement drew wide attention, but it did not make any of them eligible for compounding.
What Was Announced
The HHS announcement indicated that HHS had directed FDA to reclassify the following peptides from Category 2 back to Category 1:
- BPC-157
- Thymosin Alpha-1
- TB-500 (Thymosin Beta-4)
- CJC-1295
- Ipamorelin
- AOD 9604
- GHK-Cu
- MOTS-c
- Selank
- Semax
- KPV
- DSIP (Delta Sleep-Inducing Peptide)
- Kisspeptin-10
- GHRP-6
What Has Not Happened
None of these peptides has been moved to Category 1 or added to the 503A bulks list. Key points:
- Removed from Category 2, not approved: In April 2026, FDA removed 12 peptides from Category 2 because their nominators withdrew the nominations. Removal did not place them in Category 1 or on the 503A bulks list, so they still cannot be compounded
- Category 2 is now short: FDA’s May 14, 2026 list keeps one peptide in Category 2, Kisspeptin-10
- Advisory review, not a rule: FDA scheduled its Pharmacy Compounding Advisory Committee to discuss peptides for the 503A bulks list, with meetings in July 2026 and before the end of February 2027. Only a final rule adds a substance to the list
- No Federal Register rule: No rule adding these peptides has been published in the Federal Register
What This Means for Prescribers Right Now
Until FDA adds a peptide to the 503A bulks list or to Category 1, it cannot be compounded. The conservative legal position is:
- Verify current FDA classification status for each peptide before prescribing
- Build your program on peptides that are compoundable today, such as Sermorelin, rather than on the peptides listed above
- Monitor official sources including the FDA website and Federal Register
- Consult legal counsel about your specific risk tolerance and the current enforcement environment
Karpa does not offer BPC-157, CJC-1295/Ipamorelin, TB-500 / Thymosin Beta-4, or the other peptides listed above. For the peptides Karpa does offer, see our peptide therapy program.
State-by-State Prescribing Authority
Peptide prescribing authority is governed by both federal law (FDA classification) and state law (scope of practice, prescriptive authority). This creates a dual-layer regulatory framework.
General Prescribing Authority
In most states, the following practitioners can prescribe compounded peptides that are eligible for compounding:
- Physicians (MD/DO): Full prescriptive authority in all states
- Nurse Practitioners (NP): Prescriptive authority varies by state; some require collaborative agreements
- Physician Assistants (PA): Prescriptive authority under physician supervision in most states
- Naturopathic Physicians (ND): Limited prescriptive authority in states that license NDs
State-Specific Considerations
States vary in several important ways:
Scope of practice restrictions: Some states limit prescribing of compounded medications to physicians, while others allow mid-level providers with appropriate supervision or collaborative agreements.
Telehealth prescribing rules: States have different requirements for establishing a provider-patient relationship via telehealth. Some require an initial in-person visit; others permit fully virtual relationships. The Federation of State Medical Boards (FSMB) maintains resources on state telehealth policies.
Compounding pharmacy regulations: State boards of pharmacy may impose additional requirements on compounding pharmacies operating within their borders, which can affect medication availability.
Off-label prescribing: While off-label prescribing is generally legal for licensed physicians, some states have specific disclosure or documentation requirements.
Verifying Your State’s Requirements
Before launching a peptide therapy program, verify requirements with:
- Your state medical board: FSMB State Medical Board Directory
- Your state board of pharmacy: For compounding-specific regulations
- Your state nursing board: If NPs will be prescribing in your practice
- Healthcare legal counsel: For interpretation of ambiguous regulations
Multi-State Practice Considerations
If your practice serves patients across state lines (common with telehealth), you must comply with the regulations of:
- The state where you are licensed and physically located
- The state where the patient is physically located at the time of the encounter
- Any interstate compact requirements (if applicable)
The Interstate Medical Licensure Compact (IMLC) facilitates multi-state licensing but does not override individual state prescribing regulations.
DEA Considerations
While most therapeutic peptides are not currently scheduled controlled substances, DEA considerations remain relevant for peptide therapy practices.
Current Scheduling Status
As of 2026, no commonly prescribed therapeutic peptides (Sermorelin, etc.) are listed on the DEA’s Controlled Substances Schedules. This means:
- No DEA registration is specifically required for peptide prescribing
- No Schedule II-V prescribing requirements apply
- No DEA reporting or monitoring requirements for peptide prescriptions
- No prescription monitoring program (PMP) obligations for peptides
Why DEA Registration Still Matters
Prescribers should maintain current DEA registration because:
- Many practices prescribe controlled substances alongside peptides (e.g., testosterone in TRT programs)
- DEA registration is part of general prescriptive authority verification
- Some pharmacy systems require active DEA numbers for electronic prescribing
- If any peptide were to be scheduled in the future, you would need current registration
Growth Hormone Releasing Peptides: A Special Case
Growth hormone releasing peptides (GHRPs) and growth hormone releasing hormone (GHRH) analogs deserve special attention:
- Growth hormone itself (somatotropin) is not a controlled substance but is subject to specific federal restrictions under 21 USC 333(e), which prohibits distribution for non-medical purposes
- GHRP-6, Sermorelin: Not scheduled, but prescribers should document legitimate medical purposes
- Anti-doping considerations: Many peptides are banned by WADA and sports organizations; counsel patients who are competitive athletes
Potential Future Scheduling
Monitor DEA announcements for any scheduling actions involving peptides. If a commonly prescribed peptide were added to a controlled substance schedule, practices would need to immediately implement controlled substance protocols including secure storage, DEA Form 222 ordering, and prescription monitoring program reporting.
Informed Consent Requirements
Informed consent is both an ethical obligation and a legal requirement for peptide therapy. Because most peptide applications are off-label and the medications are compounded (not FDA-approved for the specific indication), informed consent takes on particular importance.
Essential Elements of Peptide Therapy Informed Consent
Your informed consent documentation should address:
1. Nature of the treatment
- Specific peptide(s) being prescribed
- Route of administration (subcutaneous injection, oral, nasal, topical)
- Proposed dosing protocol and duration
- Expected timeline for results
2. FDA and regulatory status
- The peptide is compounded, not an FDA-approved finished drug product
- Most peptide applications are off-label
- The regulatory classification may change
- The medication has not undergone the same clinical trial process as FDA-approved drugs
3. Benefits and risks
- Expected therapeutic benefits based on available evidence
- Known side effects and adverse reactions
- Unknown risks due to limited long-term data
- Injection site reactions (for subcutaneous administration)
4. Alternatives
- FDA-approved alternatives, if any exist
- Non-pharmacological alternatives
- Option to decline treatment
5. Compounding-specific disclosures
- The medication is prepared by a compounding pharmacy
- The name of the compounding pharmacy
- Quality controls in place (without guaranteeing equivalence to FDA-approved products)
- Storage and handling requirements
6. Patient responsibilities
- Proper self-injection technique (if applicable)
- Storage requirements (many peptides require refrigeration)
- Reporting adverse effects promptly
- Following the prescribed dosing protocol
- Attending follow-up appointments
Documentation Best Practices
- Obtain written, signed informed consent before initiating therapy
- Document the consent discussion in the clinical record (date, topics covered, patient questions)
- Update consent forms when regulatory conditions change
- Re-consent patients when adding new peptides or significantly changing protocols
- Maintain copies of all signed consent forms in the patient record
Documentation Best Practices
Thorough documentation protects prescribers, practices, and patients. For peptide therapy, documentation standards should exceed the minimum because of the off-label, compounded nature of the medications.
Clinical Documentation for Each Patient
Initial evaluation:
- Chief complaint and treatment goals
- Relevant medical history and review of systems
- Current medications (checking for interactions)
- Relevant laboratory results
- Physical examination findings (if indicated)
- Clinical assessment and plan
- Rationale for peptide therapy selection
Prescription documentation:
- Specific peptide, dose, concentration, volume, and route
- Frequency and duration
- Compounding pharmacy selected and rationale
- Any special instructions
Follow-up documentation:
- Patient-reported outcomes (symptom changes, side effects)
- Objective measures when applicable (labs, weight, body composition)
- Treatment modifications and rationale
- Ongoing informed consent (especially if adding peptides or changing protocols)
Program-Level Documentation
Beyond individual patient records, maintain:
- Standard operating procedures (SOPs) for your peptide therapy program
- Prescribing protocols that outline your clinical approach to each peptide
- Pharmacy partner documentation including Business Associate Agreements, quality certifications, and contact information
- Staff training records for clinical and administrative team members
- Adverse event logs tracking any reported adverse reactions
- Regulatory update file documenting how you monitor and respond to regulatory changes
EHR Considerations
If your EHR system does not have built-in support for compounded medication workflows, consider:
- Custom templates for peptide therapy visits
- Structured fields for informed consent documentation
- Integration with compounding pharmacy ordering systems
- Automated follow-up scheduling
- Lab result tracking linked to peptide protocols
Platforms like Karpa Health provide purpose-built clinical workflows for peptide therapy that handle documentation, pharmacy integration, and patient management.
Malpractice Considerations
Peptide therapy introduces specific malpractice risk factors that practices should address proactively.
Common Malpractice Risk Areas
Off-label prescribing liability: While off-label prescribing is legal, prescribers must demonstrate clinical rationale. Document your reasoning, cite supporting literature when available, and ensure informed consent addresses the off-label nature.
Standard of care questions: Because peptide therapy is relatively new and protocols are not universally standardized, the “standard of care” can be difficult to define. Follow published protocols from reputable sources, document your clinical decision-making, and stay current with evolving best practices.
Compounding pharmacy quality: If a patient experiences harm from a contaminated or incorrectly formulated compounded peptide, the prescribing practice may face liability questions. Mitigate this by using only reputable pharmacies with documented quality programs.
Telehealth-specific risks: If prescribing via telehealth, ensure your evaluation meets the standard of care for your state. Document that the telehealth encounter was clinically appropriate for the services provided.
Scope of practice issues: Ensure all prescribers in your practice are prescribing within their licensed scope. This is particularly important for mid-level providers.
Insurance Coverage Steps
- Contact your carrier before launching: Notify your malpractice insurance provider of your plans to offer peptide therapy
- Confirm coverage: Verify that compounded medication prescribing, off-label prescribing, and telehealth (if applicable) are covered
- Ask about exclusions: Some policies exclude “experimental” treatments; clarify whether peptide therapy falls into any exclusion
- Obtain riders if needed: If your base policy does not cover peptide therapy, ask about available riders
- Document the confirmation: Keep written confirmation of coverage in your files
Risk Mitigation Strategies
- Maintain detailed clinical documentation for every patient
- Follow established protocols and document deviations with clinical rationale
- Use only reputable compounding pharmacies with quality certifications
- Obtain thorough informed consent
- Stay within your scope of practice and training
- Participate in continuing education on peptide therapy
- Maintain open communication with patients about expectations and limitations
Compliance Checklist for Peptide Therapy Programs
Use this checklist when setting up or auditing your peptide therapy program:
Federal Regulatory Compliance
- Verify FDA category status for each peptide you plan to prescribe
- Confirm compounding pharmacy operates under valid 503A or 503B authority
- Verify no DEA scheduling applies to your peptide formulary
- Review FTC advertising requirements for claims about peptide therapy
- Ensure HIPAA compliance for patient data handling (see HIPAA guidance for cash-pay programs)
State Regulatory Compliance
- Verify prescriptive authority under your state medical board
- Confirm state board of pharmacy compounding regulations
- Review state telehealth regulations (if offering virtual consultations)
- Verify mid-level provider supervision requirements (if applicable)
- Check state-specific informed consent requirements
Clinical Infrastructure
- Develop clinical protocols for each peptide offered
- Create informed consent documents
- Establish patient screening criteria and contraindication lists
- Set up lab ordering and result monitoring workflows
- Implement adverse event reporting procedures
Business and Legal
- Confirm malpractice insurance coverage
- Execute Business Associate Agreements with pharmacy partners
- Review marketing materials for regulatory compliance
- Establish financial policies and patient payment agreements
- Document all vendor relationships and agreements
Ongoing Monitoring
- Subscribe to FDA compounding updates
- Monitor HHS announcements for policy changes
- Review state medical board communications quarterly
- Update protocols and consent forms when regulations change
- Conduct annual compliance audits
Resources for Staying Current
The peptide therapy regulatory environment changes frequently. Maintain awareness through these authoritative sources:
Federal Resources
- FDA Bulk Drug Substances Used in Compounding
- FDA Human Drug Compounding
- HHS News and Communications
- Federal Register: FDA Rules
- DEA Controlled Substances Schedules
State Resources
- FSMB State Medical Board Directory
- NABP State Board of Pharmacy Directory
- FSMB Telemedicine Policies
Professional Organizations
- Alliance for Pharmacy Compounding
- American Academy of Anti-Aging Medicine (A4M)
- International Peptide Society
How Karpa Health Supports Compliant Peptide Programs
Karpa Health provides the operational platform for practices to offer peptide therapy programs with built-in compliance infrastructure:
- Structured patient intake with customizable screening questions and consent workflows
- automated clinical review that flags contraindications and prepares clinical summaries for review by Karpa’s 50-state network of licensed providers
- Integrated prescribing to compliant compounding pharmacies with electronic prescription routing
- Documentation automation that maintains detailed clinical records
- Pharmacy partner vetting: Karpa integrates only with pharmacies that meet quality and compliance standards
The platform handles peptide therapy, GLP-1 weight loss, TRT, and HRT from a single system, allowing practices to build diversified programs efficiently.
Book a demo to see how Karpa’s compliance infrastructure works for your practice. For answers to common questions, visit our FAQ.
This article is for informational purposes only and does not constitute legal advice. Peptide therapy regulations are evolving rapidly in 2026. Consult qualified healthcare legal counsel for advice specific to your practice, state, and clinical situation. Last reviewed: May 2026.
For more context on closely related topics, read 503A vs. 503B pharmacy guide.
Book a call with Karpa Health if you want help structuring the right program.
